The melanocortin-4 receptor (MC4R) is the central satiety switch in the brain's hypothalamic energy balance circuit¹¹ hypothalamic energy balance circuit
the hypothalamus integrates signals from fat cells, gut hormones, and the brainstem to regulate hunger and energy expenditure. When the MC4R pathway is working, leptin from fat cells activates POMC neurons that release alpha-melanocyte stimulating hormone (α-MSH), which binds MC4R receptors and sends "stop eating" signals. The rs8087522 variant sits approximately 2 kilobases upstream of the MC4R gene — in the regulatory DNA that controls how much MC4R the hypothalamus produces.

This is a depth variant. The GeneOps platform already covers rs17782313²² rs17782313
the primary MC4R-region obesity GWAS signal, 188kb downstream of MC4R, which has a robust obesity association replicated in tens of thousands of participants. rs8087522 sits directly upstream of MC4R's coding sequence and tags a different aspect of MC4R regulation. Its specific clinical relevance has emerged primarily in the context of medication-induced weight gain rather than general obesity.

The Mechanism

rs8087522 is a G-to-A substitution at position 60,373,245 on chromosome 18 (GRCh38), approximately 2kb upstream of the MC4R transcription start site. MC4R itself is encoded on the minus strand, but rs8087522 alleles are reported in plus-strand orientation (G=reference, A=alternate).

In vitro electrophoretic mobility-shift assay³³ In vitro electrophoretic mobility-shift assay
EMSA: a technique where protein extracts are incubated with labeled DNA to detect transcription factor binding data from one pharmacogenomics study suggest that the A allele may create a transcription factor binding site absent in the G allele. If confirmed, this would give the A allele the capacity to alter MC4R upstream regulatory activity — potentially changing how much receptor protein is expressed in hypothalamic neurons. However, this functional evidence is limited to a single in vitro assay and has not been replicated in human brain tissue or animal models.

The nearby rs489693⁴⁴ rs489693
a variant ~158kb upstream of rs8087522 on chromosome 18, mapped near the MC4R region in GWAS studies has been independently associated with antipsychotic-induced weight gain at genome-wide significance (P=5.59×10⁻¹²), confirming that the MC4R upstream regulatory region as a whole influences medication-related energy dysregulation.

The Evidence

Direct evidence for rs8087522 is sparse and should be read honestly:

General obesity: Two studies have directly tested rs8087522 for obesity association and found none. Beckers et al. (2011)⁵⁵ Beckers et al. (2011)
association study of MC4R tagSNPs in 1,049 obese Belgian adults vs. 312 lean controls genotyped rs8087522 alongside rs17782313 and rs1943226 and found "no associations with obesity" for the upstream variants, while rs17782313 replicated strongly (OR=1.42, p=0.002). Yilmaz et al. (2015)⁶⁶ Yilmaz et al. (2015)
328 European ancestry individuals, five MC4R markers similarly found no independent rs8087522 signal for BMI or overeating behaviors.

Antipsychotic-induced weight gain: The most specific finding for rs8087522 comes from Chowdhury et al. (2012)⁷⁷ Chowdhury et al. (2012)
224 schizophrenia patients on antipsychotics, 14-week follow-up. European-ancestry patients carrying the A allele who were taking clozapine gained significantly more weight than non-carriers (P=0.027, n=69 in the clozapine subgroup). The authors caution that this association was marginal after correction for multiple testing and described the findings as exploratory, warranting further investigation. The proposed mechanism — A-allele creation of a transcription factor binding site (confirmed by EMSA) — adds biological plausibility, but the clinical signal remains unconfirmed.

The broader context for MC4R upstream variants in antipsychotic weight gain is stronger. The nearby rs489693 reached genome-wide significance in a multi-cohort study of 344 pediatric and adult patients (meta-analysis P=5.59×10⁻¹²), with minor allele homozygotes gaining substantially more weight on second-generation antipsychotics including clozapine, olanzapine, and quetiapine. The rs489693 finding has been independently replicated, making the MC4R upstream region a credible antipsychotic pharmacogenomics locus even if the specific contribution of rs8087522 within that region remains to be established.

Practical Implications

For individuals prescribed clozapine specifically, A-allele status at rs8087522 may be one element of a broader MC4R-region pharmacogenomic risk profile. Clozapine is disproportionately associated with weight gain among antipsychotics — average gain of 4-6 kg over the first year — and MC4R pathways are mechanistically implicated in how the drug suppresses hypothalamic satiety neurons. The A allele's potential to alter MC4R upstream regulation means that individuals carrying it on clozapine may warrant closer metabolic monitoring from the start of treatment.

For general weight management outside of antipsychotic use, the current evidence does not support rs8087522 as an independent risk factor. The primary MC4R-region signal for common obesity risk remains rs17782313, which has a well-established, large-cohort evidence base.

Interactions

rs17782313 (the primary MC4R-region obesity variant): rs17782313 is located 188kb downstream of MC4R in a separate regulatory block and has a robust, independent obesity association. rs8087522 sits in the proximal upstream region and has been tested in studies alongside rs17782313 — in those studies, the two variants do not show correlated effects on obesity. They likely tag different aspects of MC4R regulation and should be interpreted independently.

rs489693 (MC4R-region antipsychotic pharmacogenomics variant): rs489693 lies roughly 157kb from rs8087522 on chromosome 18 and has a strong, replicated association with antipsychotic-induced weight gain (genome-wide significance in multi-cohort GWAS). Both variants tag the MC4R regulatory region in the context of drug-induced weight gain, and their combined effect has not been formally studied. Individuals carrying risk alleles at both loci may face amplified antipsychotic weight gain risk, though this is speculative without published compound-genotype data.

Cathepsin S (CTSS) is a lysosomal cysteine protease with an indispensable role at the heart of adaptive immunity: it is the primary enzyme that cleaves the invariant chain (Ii/CD74) from MHC class II molecules¹¹ MHC class II molecules
MHC class II is the cellular machinery that presents antigens to CD4+ T helper cells, initiating and shaping immune responses, enabling antigen loading and T-cell activation. When CTSS function is altered — whether by genetic variation or pathological upregulation — the cascade of T-cell priming and inflammatory cytokine production shifts in ways that promote atopic disease. This variant in the CTSS locus was identified as a novel atopic dermatitis risk locus in a large GWAS meta-analysis, underscoring a fundamentally immunological origin for eczema susceptibility.

The Mechanism

In professional antigen-presenting cells (dendritic cells, B cells, and macrophages), CTSS is the rate-limiting protease for removing the invariant chain from MHC class II molecules inside endosomes. Without efficient CTSS activity, peptide loading onto MHC class II is impaired; with excess CTSS activity, antigen presentation is amplified and self-tolerance can break down. Cathepsin S-deficient mice accumulate Ii-MHC II complexes and show severely impaired CD4+ T-cell responses²² Cathepsin S-deficient mice accumulate Ii-MHC II complexes and show severely impaired CD4+ T-cell responses
Riese et al. demonstrated that specific cathepsin S inhibition in B lymphoblastoid cells prevented complete proteolysis of the invariant chain and blocked SDS-stable peptide-loaded complexes.

Beyond its role in classical antigen presentation, CTSS is also secreted extracellularly by skin-resident dendritic cells and keratinocytes, where it activates proteinase-activated receptor 2 (PAR2)³³ activates proteinase-activated receptor 2 (PAR2)
PAR2 activation by CTSS triggers downstream TRPV1 signaling in sensory neurons on sensory nerve endings — directly triggering itch. This dual role in both antigen presentation and pruritus makes CTSS a mechanistically coherent risk gene for atopic dermatitis, which is defined by both immune dysregulation and chronic itch.

The rs187080438 T allele is an intronic variant in the flanking RPRD2 gene approximately 328 kb upstream of CTSS on chromosome 1q21. Although the variant itself does not alter any CTSS protein residue, GWAS loci routinely act through cis-eQTL mechanisms⁴⁴ cis-eQTL mechanisms
expression quantitative trait loci regulate the level of nearby gene transcription in a tissue-specific manner, commonly in immune cell types that alter gene expression levels, particularly in the immune cell types where CTSS is most active. The full mechanistic link between this specific intronic variant and CTSS expression changes in human immune cells awaits functional follow-up.

The Evidence

Budu-Aggrey et al. (2023, Nature Communications)⁵⁵ Budu-Aggrey et al. (2023, Nature Communications)
European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation. Nat Commun. 2023;14(1):6280 conducted a GWAS meta-analysis including 65,107 atopic dermatitis cases and 1,021,287 controls in the European discovery phase, plus a multi-ancestry expansion to 765,209 individuals. Rs187080438 emerged as one of 29 novel loci genome-wide (OR=1.17, 95% CI 1.11–1.23, p=3.7×10⁻¹⁰). The finding replicated robustly in an independent 23andMe European cohort of 2,904,664 individuals (OR=1.14, p=2.0×10⁻⁴¹), making false-positive inflation highly unlikely. The CTSS gene was nominated as the most biologically plausible candidate given its tissue expression profile and established role in immune regulation.

The animal model evidence is compelling: Kim et al. (2012)⁶⁶ Kim et al. (2012)
Overexpression of cathepsin S induces chronic atopic dermatitis in mice. J Invest Dermatol. 2012;132(4):1169–76 showed that CTSS-overexpressing transgenic mice spontaneously develop a chronic atopic dermatitis-like skin disorder with PAR-2 upregulation, scratching behavior, and altered T-helper cytokine profiles. Separately, Chung et al. (2019)⁷⁷ Chung et al. (2019)
Cathepsin S acts via protease-activated receptor 2 to activate sensory neurons and induce itch-like behaviour. Neurobiol Pain. 2019 established the itch pathway: injected human recombinant CTSS caused dose-dependent scratching in mice that was abolished by PAR2 antagonists and reduced 50% in TRPV1-knockout mice. This convergent evidence — GWAS signal, transgenic mouse model, mechanistic itch pathway — places CTSS among the more biologically grounded novel AD loci. The evidence level is rated moderate: the GWAS association is well-powered and replicated, but functional confirmation of rs187080438's effect on CTSS expression in human tissue is not yet published.

Practical Actions

The T allele is present in roughly 2–3% of Europeans and is extremely rare in East Asian and African populations, indicating this locus contributes primarily to AD risk in European-ancestry individuals. For carriers, the OR of 1.17 represents a modest but statistically robust elevation in atopic dermatitis risk.

Because the biological mechanism is CTSS-mediated antigen dysregulation and PAR2-driven itch, practical management focuses on reducing the downstream consequences: attenuating type 2 immune skewing, protecting the skin barrier to limit the antigen challenge that CTSS amplifies, and addressing the PAR2-itch axis. Emollient therapy that maintains barrier integrity reduces the antigen load reaching dendritic cells and thus the antigen-presentation amplification that elevated CTSS activity drives.

Serine/cysteine protease inhibitors targeting CTSS are under active investigation as therapeutic targets for atopic dermatitis and asthma — carriers of this locus may be particularly responsive to this class of emerging therapies.

Interactions

Two additional CTSS-region variants (rs146527530 and rs115161931) were identified as independent signals in the same GWAS meta-analysis, at positions 151,059,196 and 151,063,299 (GRCh38) with ORs of 1.27 and 1.18 respectively. These may reflect distinct regulatory mechanisms acting on CTSS or on nearby genes. Co-occurrence of multiple CTSS-locus risk alleles could compound individual risk; compound action evidence across these variants has not yet been formally studied.

Within the broader AD genetic architecture, CTSS operates downstream of the epithelial barrier (FLG, SPINK5, KIF3A) and upstream of adaptive immune polarization (STAT6, IL13, IL4). Individuals with both barrier-gene defects and CTSS-locus risk may face an amplified antigen-presentation burden, as more antigens penetrate the defective barrier and encounter a sensitized CTSS-driven presentation pathway.

The SHMT1 gene encodes serine hydroxymethyltransferase 1, a pyridoxal phosphate (vitamin B6)-dependent enzyme¹¹ pyridoxal phosphate (vitamin B6)-dependent enzyme
SHMT1 requires vitamin B6 as a cofactor that sits at a critical junction in one-carbon metabolism²² one-carbon metabolism
the folate cycle that provides methyl groups for DNA synthesis, repair, and methylation. SHMT1 converts serine and tetrahydrofolate into glycine and 5,10-methylenetetrahydrofolate, supplying one-carbon units for thymidylate synthesis (DNA building blocks) and methylation reactions. The C1420T variant causes a leucine-to-phenylalanine substitution at position 474 of the protein, altering its cellular localization and affecting how efficiently the enzyme channels one-carbon units through different metabolic pathways.

The Mechanism

The Leu474Phe amino acid change affects the enzyme's cellular distribution³³ affects the enzyme's cellular distribution
The T allele alters SHMT1 localization within cells, reducing availability of 5,10-methylenetetrahydrofolate rather than simply destroying its activity. SHMT1 normally shuttles between the cytoplasm and nucleus during DNA replication, providing one-carbon units directly where they're needed. The 1420T variant appears to disrupt this trafficking, causing the enzyme to favor certain metabolic routes over others. Specifically, it may reduce the supply of methylenetetrahydrofolate⁴⁴ reduce the supply of methylenetetrahydrofolate
substrate required by the MTHFR enzyme that converts it to methylfolate for homocysteine remethylation. This creates a metabolic bottleneck: less substrate available for MTHFR, potentially leading to elevated homocysteine if folate intake is marginal.

Intriguingly, individuals with the CC genotype have lower plasma and red blood cell folate levels⁵⁵ individuals with the CC genotype have lower plasma and red blood cell folate levels
Study of neural tube defect families found significantly decreased folate in CC carriers compared to T allele carriers — the opposite of what you might expect given the T allele's functional changes. This paradox likely reflects a compensatory redistribution: the T variant shifts folate derivatives toward different storage forms or compartments rather than simply depleting them. The clinical consequences depend on which metabolic pathway matters most for a given condition.

The Evidence

The most robust data come from cancer association studies⁶⁶ cancer association studies
Multiple meta-analyses with tens of thousands of participants. A meta-analysis of 7,309 lymphoma patients⁷⁷ meta-analysis of 7,309 lymphoma patients
3,232 cases and 4,077 controls across eight studies found the TT genotype modestly increases non-Hodgkin lymphoma risk (OR = 1.18), with borderline significance. The association is stronger for the T allele in general (OR = 1.09, p = 0.025), suggesting a dose-dependent effect. Mechanisms likely involve impaired DNA synthesis or methylation during rapid immune cell proliferation.

Conversely, a meta-analysis of 31,405 solid tumor cases⁸⁸ meta-analysis of 31,405 solid tumor cases
14,409 cases and 16,996 controls from 23 studies revealed the TT genotype protects against breast cancer in Asian populations (OR = 0.79, p = 0.003), though not in Caucasians. A similar protective effect appears for rectal cancer⁹⁹ rectal cancer
Study of 476 rectal cancer patients in Hungary, where TT carriers had 43% lower risk (OR = 0.57). For acute lymphoblastic leukemia¹⁰¹⁰ acute lymphoblastic leukemia
Univariate analysis in adults, the TT genotype conferred a striking 3.3-fold risk reduction (OR = 0.31). These protective effects may arise from altered folate partitioning that reduces availability of nucleotides for rapidly dividing cancer cells.

The cardiovascular story involves gene-gene interactions¹¹¹¹ gene-gene interactions
SHMT1 and MTHFR polymorphisms interact to influence CVD risk. In the Nurses' Health Study, women carrying both SHMT1 TT and MTHFR 677 CT genotypes faced 4.3-fold increased cardiovascular disease risk compared to women with CC for both variants. The mechanism: reduced substrate (5,10-methylenetetrahydrofolate) from SHMT1 TT compounds the impaired enzyme activity from MTHFR 677T, creating a severe bottleneck in homocysteine remethylation. Elevated homocysteine and C-reactive protein together predict worse cardiovascular outcomes¹²¹² Elevated homocysteine and C-reactive protein together predict worse cardiovascular outcomes
Prospective study of 291 stroke patients over 5 years, with combined high levels raising risk 4.67-fold.

Practical Implications

If you carry one or two T alleles, your folate metabolism is functional but may be less efficient at certain steps, particularly the conversion of folate intermediates into methylfolate for homocysteine metabolism. The clinical relevance depends heavily on context — your folate intake, the status of other folate-cycle genes (especially MTHFR), and which tissues are most metabolically active.

For cardiovascular protection¹³¹³ cardiovascular protection
SHMT1 interacts with MTHFR to influence heart disease risk, prioritize methylfolate over synthetic folic acid, especially if you also carry MTHFR 677T or 1298C variants. The SHMT1-MTHFR interaction can significantly elevate homocysteine, an independent risk factor for atherosclerosis. Consider periodic homocysteine testing (ideal range: <10 μmol/L) to monitor whether your folate metabolism is keeping up with demand.

The cancer associations are complex and context-dependent. The T allele may increase risk for blood cancers involving rapid immune cell division, but appears protective against some solid tumors. This isn't a call to avoid or embrace the variant — it's fixed in your DNA — but rather a reminder that optimal folate status matters. Adequate B vitamin intake supports proper DNA synthesis and repair regardless of genotype.

Interactions

SHMT1 C1420T interacts most notably with MTHFR C677T (rs1801133) and A1298C (rs1801131). When SHMT1 TT reduces the supply of 5,10-methylenetetrahydrofolate, and MTHFR 677T reduces the enzyme's ability to convert that substrate, the combined effect significantly impairs methylfolate production and homocysteine remethylation. This gene-gene interaction substantially increases cardiovascular disease risk beyond either variant alone, particularly in the context of marginal folate intake. Individuals with both SHMT1 TT and MTHFR 677 CT or TT genotypes should prioritize methylfolate supplementation and monitor homocysteine levels.

SHMT1 also functions in the same pathway as SLC19A1 G80A (RFC1, rs1051266), the main folate transporter into cells, and MTRR A66G (rs1801394), which recycles methionine synthase. Variants in these genes can compound SHMT1-related inefficiencies by further limiting folate availability or homocysteine remethylation capacity.

Glucokinase¹¹ Glucokinase
GCK (hexokinase-4): the enzyme that phosphorylates glucose to glucose-6-phosphate in pancreatic beta cells and hepatocytes, functioning as the pancreas's molecular glucose sensor. Its kinetic properties require high glucose to activate, making it the gatekeeper of glucose-stimulated insulin secretion. (GCK) is one of the most consequential metabolic genes in the human genome. Rare loss-of-function mutations cause MODY2 — lifelong mild fasting hyperglycemia. Activating mutations cause congenital hyperinsulinism. Common intronic variants such as rs4607517 are among the most robustly replicated loci for fasting glucose in large-scale GWAS. rs2268574 is a different intronic variant in the same gene, located 38 nucleotides downstream of exon 7 in intron 7, with a more limited and less consistent evidence record.

The Mechanism

rs2268574 (GRCh38 chr7:44149722; coding-strand notation: c.679+38T>G) sits well within intron 7 of GCK, 38 base pairs downstream of the exon 7 splice donor site. At this distance from the canonical splice site, classical splice-disrupting effects are unlikely. The variant does not alter any glucokinase protein sequence. Its potential functional mechanism — if any — would be regulatory, perhaps through intronic enhancer activity or effects on mRNA secondary structure, but no functional characterization has been published for this specific variant.

The A allele (the GRCh38 reference) is the population-minor allele globally (~43%), while the G allele predominates (~57% worldwide). The A allele is somewhat more common in Europeans (~51%) and South Asians (~56%) than in East Asians (~37%) or Africans (~27%), suggesting some population stratification that could confound association studies not appropriately controlling for ancestry.

The Evidence

The evidence base for rs2268574 is small and inconsistent. A 2014 communication²² 2014 communication
Frigeri HR et al. The polymorphism rs2268574 in Glucokinase gene is associated with gestational Diabetes mellitus. Clin Biochem 2014. PMID:24495862 from a Brazilian group reported an association between the A allele and gestational diabetes mellitus (GDM). However, this study is a brief communication with no published abstract, and independent details such as sample size, odds ratios, and population ancestry are not publicly accessible.

The same research group subsequently tested rs2268574 in obese women with type 2 diabetes and found no significant association³³ no significant association
Frigeri HR et al. Polymorphisms rs144723656, rs2268574, and rs2268575 of the glucokinase gene are not associated with obese women with type 2 diabetes mellitus. Clin Biochem 2016. PMID:26436570. A larger Chinese case-control study with 835 GDM patients and 870 controls also found no significant association⁴⁴ no significant association
She L et al. Association of glucokinase gene and glucokinase regulatory protein gene polymorphisms with gestational diabetes mellitus: a case-control study. Gene 2022. PMID:35276241 between rs2268574 and GDM (P > 0.05). That same study did find the neighboring promoter variant rs1799884 (GCK -30G>A, a distinct locus ~40 kb upstream) to be significantly associated, highlighting that the GCK gene contributes to GDM susceptibility through other variants — but not necessarily through rs2268574.

ClinVar classifies the G allele of rs2268574 as Benign (RCV000832813), reflecting the lack of established pathogenicity. Overall, the evidence for rs2268574 as a functional disease variant is emerging at best — one small positive signal, two negative studies, and no mechanistic characterization.

Practical Actions

The weak and inconsistent evidence for rs2268574 means that no strongly evidence-based genotype-specific intervention can be prescribed. For individuals carrying the A allele (particularly AA homozygotes) with concern about gestational diabetes or glucose metabolism, standard GCK-pathway monitoring applies: fasting glucose and HbA1c provide the most actionable information about glucokinase function regardless of which specific GCK variant is present.

Interactions

rs2268574 is located in the same GCK gene as several other catalogued variants with stronger and better-characterized evidence: rs4607517 (a robustly replicated GWAS locus for fasting glucose in up to 122,744 individuals), and rs1799884 (the GCK -30G>A promoter variant with established GDM association in multiple European cohorts). These represent stronger evidential anchors for GCK-related metabolic risk than rs2268574 itself. rs10278336 is another intronic GCK variant studied in the same Chinese GDM cohort (She 2022) that also showed no independent association with GDM.

CYP2E1 (cytochrome P450 2E1) is the liver enzyme responsible for metabolizing a remarkably diverse set of substrates: acetaminophen (paracetamol), isoniazid (a front-line antibiotic for tuberculosis), ethanol at high concentrations, volatile anesthetics such as halothane, and a range of industrial solvents including benzene, styrene, and trichloroethylene. The rs2515641 variant in exon 8 is [synonymous | a synonymous variant changes the DNA sequence but not the amino acid in the resulting protein] — it substitutes thymine for cytosine at position 1263 in the coding sequence (c.1263C>T), leaving phenylalanine at position 421 unchanged (p.Phe421=). Yet despite producing no amino acid change, it demonstrably reduces how much CYP2E1 the body makes.

The Mechanism

Synonymous variants were once dismissed as functionally inert, but rs2515641 illustrates how altered [codon usage | Codon usage bias: different codons for the same amino acid can differ in translation speed and mRNA stability] can reshape enzyme expression. The c.1263C>T substitution changes a common codon to a rarer one; the result is reduced mRNA stability and slower translation elongation, yielding lower CYP2E1 at both the transcript and protein level. Chen et al. (2020)¹¹ Chen et al. (2020)
Chen K, Guo R, Wei C. Synonymous mutation rs2515641 affects CYP2E1 mRNA and protein expression and susceptibility to drug-induced liver injury. Pharmacogenomics, 2020;21(7):459-470. demonstrated this directly in HepG2 hepatoma cells transfected with lentiviral vectors carrying either the C (wild-type) or T (variant) allele: cells expressing the T allele showed significantly lower CYP2E1 mRNA and protein, and the response of CYP2E1 expression to acetaminophen or triptolide challenge was dramatically altered. rs2515641 is also in complete linkage disequilibrium with [rs2070676 (CYP2E1*1B) | rs2070676, also called CYP2E1*1B, is an intronic variant frequently co-inherited with rs2515641], a variant used as a tag SNP for this genomic region across diverse populations.

The Evidence

For isoniazid toxicity, the most directly clinically documented effect, Yu et al. (2019)²² Yu et al. (2019)
Yu YY et al. Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis. IJERPH, 2019 enrolled 377 patients on a rifapentine-isoniazid regimen for latent tuberculosis. Those carrying the CT or TT genotype had 1.85–1.90-fold increased odds of developing adverse drug reactions (OR 1.850, 95% CI 1.193–2.870 for CT; OR 1.903, 95% CI 1.250–2.898 for CT+TT combined; p=0.003). The T allele itself conferred a 1.70-fold increase (95% CI 1.200–2.421). Isoniazid is metabolized by CYP2E1 into hepatotoxic intermediates; reduced enzyme capacity paradoxically increases systemic isoniazid exposure, raising toxicity risk.

For anti-TB hepatitis more broadly, Tang et al. (2013)³³ Tang et al. (2013)
Tang S et al. Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohort. PLoS One, 2013 found a minor allele frequency of 20.8% in hepatitis cases vs 18.2% in 356 matched controls (n=4,304 total TB cohort), but this difference was not statistically significant, suggesting that rs2515641 alone does not dominate risk in all populations. Effect size appears to differ substantially between Chinese and Taiwanese cohorts, likely reflecting population-level LD differences and co-exposure patterns.

For acetaminophen, the in vitro Chen et al. data suggest that reduced CYP2E1 expression in T carriers produces less [NAPQI | N-acetyl-p-benzoquinone imine (NAPQI): the toxic metabolite of acetaminophen responsible for liver injury at overdose], the toxic oxidative metabolite responsible for acetaminophen-induced liver failure. However, this does not mean T carriers are fully protected — CYP3A4 and CYP1A2 can compensate at high doses. No large clinical outcome study has confirmed this in humans for this specific SNP.

Population-level [haplotype analysis | Lee et al. (2008) examined 11 CYP2E1 polymorphisms in 2,657 individuals from 50 populations] shows markedly different T-allele frequencies across ancestry groups, with African populations carrying the T allele at ~59% — far above European (~12%) or East Asian (~17%) frequencies — making ancestry a critical variable when interpreting clinical studies predominantly drawn from Han Chinese or European cohorts.

Practical Actions

T allele carriers — particularly CT and TT individuals — face a measurably higher risk of adverse reactions when prescribed isoniazid-containing regimens. Informing a prescribing clinician or infectious disease specialist before starting isoniazid-containing tuberculosis therapy allows proactive liver enzyme monitoring. Dose timing and duration of exposure are key modifiable variables.

For acetaminophen, the practical implication is that standard labelled doses remain appropriate, but T carriers should be especially cautious with high-dose or chronic acetaminophen use, and should avoid stacking it with alcohol, which competes for the same pathway. CYP2E1 is also induced by chronic alcohol use, meaning T carriers who drink regularly may paradoxically upregulate their enzyme back toward normal levels.

Interactions

CYP2E1 expression is strongly induced by chronic ethanol, fasting/ketosis, isoniazid itself, and obesity. A T carrier whose CYP2E1 is already reduced at baseline can have that reduction partially reversed by alcohol-induced enzyme induction. Conversely, combining isoniazid with alcohol in a T carrier amplifies both the metabolic burden and the hepatotoxicity risk. Concurrent use of other CYP2E1 substrates (chlorzoxazone, halothane, certain solvents) with isoniazid or acetaminophen creates additive competitive inhibition that the T carrier's lower enzymatic reserve may not accommodate.

Peroxisome proliferator-activated receptor delta (PPARδ) is the master regulator of fatty acid beta-oxidation¹¹ Fatty acid beta-oxidation is the process of breaking down fat molecules into acetyl-CoA for energy production, primarily in skeletal muscle and heart in skeletal muscle, heart, and liver. Think of it as the dial controlling how efficiently your body uses fat as fuel. PPARδ activation boosts fat burning, preserves insulin sensitivity, improves cholesterol profiles, and supports endurance capacity. The rs3734254 T+294C variant sits in the 3' untranslated region of PPARD and appears to reduce PPARD transcript stability or expression — subtly turning that dial down.

The Mechanism

The T+294C variant lies within the 3' UTR (untranslated region) of the PPARD gene on chromosome 6. The 3' UTR regulates mRNA stability, translational efficiency, and tissue-specific expression. Variants in this region can alter binding sites for microRNAs or RNA-binding proteins, changing how much functional PPARδ protein is ultimately produced. The C allele appears to reduce PPARD expression relative to the common T allele, particularly in metabolically active tissues. Because PPARδ directly drives the transcription of genes encoding enzymes involved in fatty acid oxidation (CPT1, HADHA), glucose uptake, and mitochondrial biogenesis, reduced expression impairs the full range of metabolic benefits downstream.

The Evidence

The clearest human evidence comes from the STOP-NIDDM trial²² STOP-NIDDM trial
Andrulionyte et al. SNPs of PPARD in combination with PGC-1A and PPARG2 predict conversion from IGT to T2D. Diabetes, 2006, which followed 769 individuals with impaired glucose tolerance. In the placebo group, carriers of the rare C allele at rs3734254 combined with the PGC-1A Gly482Ser allele (rs8192678) had up to 2.5-fold higher risk of progressing to type 2 diabetes compared to those carrying the common alleles.

The Tübingen Lifestyle Intervention Program Stefan et al.³³ Stefan et al.
Stefan et al. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab, 2007 provided striking evidence of how much PPARD genotype constrains response to exercise and diet: after 9 months of supervised lifestyle intervention, participants carrying minor alleles in both PPARD and PPARGC1A gained only +4% insulin sensitivity, compared to +40% in major allele homozygotes — a tenfold difference in response.

Whole-body MRI data from Thamer et al.⁴⁴ Thamer et al.
Thamer et al. Variations in PPARD determine the change in body composition during lifestyle intervention: a whole-body magnetic resonance study. J Clin Endocrinol Metab, 2008 showed that related PPARD SNPs independently predicted smaller reductions in visceral fat, hepatic fat, and less muscle gain during a lifestyle intervention program in 156 at-risk individuals — connecting this gene family to the distribution, not just amount, of fat.

Interestingly, the CC homozygous genotype was inversely associated with lung and upper aero-digestive tract cancer mortality in a large observational study Yang et al.⁵⁵ Yang et al.
Yang et al. Polymorphisms of peroxisome proliferator-activated receptors and survival of lung cancer and upper aero-digestive tract cancers. Lung Cancer, 2014 (aHR=0.63 for lung cancer; 0.51 for UADT cancers), suggesting context-specific effects that differ between metabolic and oncological outcomes.

Practical Actions

For C allele carriers, the core challenge is that standard-intensity exercise and dietary changes produce a blunted metabolic return. The evidence from Stefan et al. and Thamer et al. points specifically toward the type and intensity of fat metabolism training: higher volumes of prolonged aerobic work at fat-burning intensities (Zone 2), together with a deliberate reduction in saturated fat and total long-chain fat load, may be needed to compensate for lower baseline PPARδ-driven fat oxidation.

Monitoring fasting glucose and insulin periodically gives early warning if metabolic progression is occurring — particularly important given the T2D conversion signal in the STOP-NIDDM trial.

Interactions

rs3734254 interacts most strongly with the PGC-1A Gly482Ser variant (rs8192678 in PPARGC1A) — the STOP-NIDDM data show that the two-gene combination produces risk far exceeding either alone. Within the PPARD gene itself, rs3734254 forms haplotypes with rs2267668, rs2016520, and rs6902123, the three fitness-category PPARD variants associated with aerobic fitness response and athlete performance.

FOXO3 is the most consistently replicated human longevity gene, with associations validated across every major population group. While multiple intronic variants in FOXO3 tag longevity haplotypes, most are statistical proxies — markers in linkage disequilibrium with the true functional variant. rs4946935 is different: it is one of only two FOXO3 variants with direct experimental proof of allele-specific function, making it the mechanistic anchor of the largest FOXO3 longevity haplotype.

Flachsbart et al. 2017¹¹ Flachsbart et al. 2017
Identification and characterization of two functional variants in the human longevity gene FOXO3. Nat Commun. 2017 resequenced the entire FOXO3 locus and genotyped 3,476 long-lived individuals and controls across German, French, and Danish cohorts. From 122 candidate variants, two emerged with both strong association signals and functional evidence: rs12206094 and rs4946935. Of the two, rs4946935 carried the lowest p-value in the combined meta-analysis (OR = 1.19, p = 2.38×10⁻⁵), and was subsequently confirmed as the lead SNP in the largest four-cohort centenarian study conducted to date.

The Mechanism

rs4946935 sits in intron 3 of FOXO3 at chromosomal position 108,679,539 (GRCh38, chromosome 6). The G→A transition creates a de-novo binding site for serum response factor (SRF)²² serum response factor (SRF)
a transcription factor in the MAPK/ERK pathway that responds to growth factor signaling and extracellular stress. Critically, SRF is not constitutively active at this site — its binding and the enhancer activity it drives are specifically and substantially suppressed by IGF-1 treatment in reporter assays.

This IGF-1 reversibility connects rs4946935 directly to the insulin/IGF-1 signaling (IIS) pathway — the most deeply conserved longevity pathway in biology, from yeast and worms to mice and humans. When circulating IGF-1 is high (as during high-protein feeding, rapid growth, or insulin resistance), IIS suppresses FOXO3 through AKT-mediated phosphorylation and cytoplasmic sequestration — and the same signaling environment also suppresses the rs4946935 SRF enhancer. When IGF-1 is low (fasting, caloric restriction, plant-protein predominance), both the SRF enhancer and FOXO3 nuclear activity are released simultaneously, compounding the longevity signal.

The rs4946935 haplotype is structurally and mechanistically distinct from the other major FOXO3 longevity locus at rs2802292, which operates through HSF1 (heat shock factor 1)³³ HSF1 (heat shock factor 1)
a stress-response transcription factor activated by heat, oxidative damage, and proteotoxic stress. HSF1 responds to cellular damage stress; SRF responds to nutrient and growth factor status. They are independent FOXO3 regulatory switches — additive in effect, complementary in stimulus.

In line with the enhancer model, eQTL analyses confirm that the A allele of rs4946935 is associated with higher FOXO3 mRNA expression across multiple human tissues. The A allele is also in strong linkage disequilibrium (r²=0.96) with rs1935949, another shipped FOXO3 longevity variant — the two variants tag the same regulatory haplotype and report concordant results in virtually all genome data.

The Evidence

The primary evidence comes from three layers: functional assays, European cohort replication, and cross-population meta-analysis.

Functional validation: Flachsbart et al. 2017⁴⁴ Flachsbart et al. 2017 confirmed SRF binding to the A allele by electrophoretic mobility shift assay (EMSA), then demonstrated allele-specific enhancer activity in luciferase reporter assays. Critically, adding IGF-1 to the culture medium significantly reduced reporter activity in cells with the longevity A allele, confirming that the enhancer is responsive to the same IIS pathway that regulates FOXO3 protein localization. This dual convergence — both the enhancer and the protein — on the same nutrient-sensing pathway is a striking mechanistic coherence.

Cohort replication: The German discovery cohort (1,109 LLI ≥95 years including 594 centenarians, 918 controls aged 60–75) showed OR = 1.35 for centenarians (p = 0.0003). This replicated in a French cohort (1,264 LLI aged 91–115 years, 1,830 controls) at OR = 1.14, p = 0.022, and trended in the same direction in a Danish cohort (643 LLI, 746 controls, OR = 1.14, p = 0.127).

Cross-population meta-analysis: Bae et al. 2018⁵⁵ Bae et al. 2018
Effects of FOXO3 Polymorphisms on Survival to Extreme Longevity in Four Centenarian Studies. J Gerontol A Biol Sci Med Sci. 2018 pooled data from the Long Life Family Study, New England Centenarian Study, Southern Italian Centenarian Study, and Longevity Genes Project — 2,072 cases and 6,194 controls. rs4946935 emerged as the SNP with the lowest p-value across all FOXO3 variants tested (OR = 1.20, p = 3.20×10⁻⁵). The A allele was enriched in long-lived individuals in all four cohorts.

Important nuance: The Bae 2018 analysis also examined whether rs4946935 predicts survival to the most extreme ages (beyond the 1st percentile for the 1900 birth cohort). The survival advantage was statistically significant for reaching very old age (~90–99 range) but not for survival past that threshold specifically — suggesting this variant helps people reach advanced old age, but centenarian status at the extreme tail reflects additional factors.

Practical Implications

The IGF-1 responsiveness of this SRF enhancer is the clearest dietary signal in the FOXO3 longevity genetics literature. Interventions that lower circulating IGF-1 specifically activate this regulatory mechanism. The most evidence-based dietary approach is a shift toward plant protein: animal protein (especially dairy and red meat) is the strongest macronutrient driver of circulating IGF-1; plant proteins (legumes, tofu, nuts) produce substantially lower IGF-1 responses. Controlled feeding studies show serum IGF-1 can fall 15–25% within weeks of shifting to predominantly plant protein while maintaining adequate total protein intake.

Time-restricted eating and periodic fasting also lower IGF-1 acutely and chronically, providing additional windows during which the SRF enhancer at rs4946935 is maximally active. These interventions are complementary to the exercise-based HSF1 activation that benefits the rs2802292 longevity locus — carriers of protective alleles at both sites can stack both dietary (IIS reduction) and stress-response (hormetic exercise) strategies.

The A allele frequency of ~30% in Europeans means the majority of people of European descent carry at least one copy (AG ~42%, AA ~9%). This is not a rare variant — it is a common regulatory polymorphism with replicated functional evidence, placing it among the most actionable findings in longevity genetics.

Interactions

rs4946935 and rs1935949 are in near-perfect LD (r²=0.96) and tag the same regulatory haplotype. Individuals with genome data from chips that captured one but not the other will receive equivalent information from either variant. The SRF enhancer mechanism described above applies to both as proxies of the same functional allele.

rs4946935 and rs2802292 are in different haplotype blocks and respond to different cellular signals: the SRF enhancer at rs4946935 responds to nutrient status (low IGF-1 during fasting or plant-protein diet), while the HSF1 enhancer at rs2802292 responds to cellular stress (heat, oxidative damage, proteotoxic stress). Carriers of protective alleles at both sites activate FOXO3 through two independent mechanisms, suggesting additive longevity benefit that targets different lifestyle interventions simultaneously.

rs12206094 is the second independently validated functional FOXO3 variant from the Flachsbart 2017 study. It involves CTCF binding rather than SRF, placing it in a distinct regulatory context. The combined genotype OR for carrying longevity alleles at both rs12206094 and rs4946935 substantially exceeds either alone.

SYPL2 (synaptophysin-like 2, also known as MG29) encodes a membrane protein related to synaptophysin, a major constituent of synaptic vesicles. In the context of metabolism, SYPL2 is expressed in adipose tissue and skeletal muscle and appears to influence fat cell biology and the response to physical activity. The rs62623713 variant introduces a missense substitution — glutamic acid to glycine at position 99 (E99G) — in a protein already implicated in adipose function by animal studies showing that mice lacking Sypl2 display reduced body weight¹¹ mice lacking Sypl2 display reduced body weight
Jiao et al., European Journal of Human Genetics, 2015.

The G allele is rare globally (approximately 4–6% in Europeans, under 0.1% in East Asians), placing this variant in the category of low-frequency coding variants rather than common GWAS polymorphisms. Its rarity made it invisible to early GWAS arrays, requiring exome sequencing to discover — a study design that is increasingly revealing low-frequency variants with larger per-allele effect sizes than common SNPs.

The Mechanism

The E99G substitution replaces a charged glutamic acid with the smallest amino acid, glycine, at position 99 of the SYPL2 protein. This change occurs in the cytoplasmic domain of the protein, potentially altering its interaction with intracellular partners involved in vesicular trafficking and membrane dynamics. Although computational predictions (SIFT score 0.58, PolyPhen score 0.0) classify the substitution as "tolerated" and "benign," these scores reflect evolutionary conservation rather than quantitative metabolic effects, and the observed human phenotype suggests functionally relevant consequences in adipose tissue not captured by these algorithms.

SYPL2 expression is notably down-regulated in less physically active children²² down-regulated in less physically active children
Galmés et al., Scientific Reports, 2023, alongside other genes associated with cardiometabolic benefit. This positions SYPL2 at the intersection of physical activity response and metabolic phenotype, though the precise molecular pathway linking E99G to increased adiposity remains to be fully characterized.

The Evidence

The primary discovery came from a 2015 exome sequencing study³³ 2015 exome sequencing study
Jiao H et al., European Journal of Human Genetics by researchers at Karolinska Institutet. Using pooled exome sequencing in 100 morbidly obese and 100 normal-weight Swedish subjects, followed by validation in 3,197 genotyped individuals, they identified rs62623713 as a low-frequency (minor allele frequency 2.9%) non-synonymous variant with striking effect size: each G allele increased BMI by 2.13 kg/m² (95% CI: 1.09–3.18, p = 6.28 × 10⁻⁵) and conferred an odds ratio of 1.32 for morbid obesity. This effect size is notably larger than common obesity variants⁴⁴ notably larger than common obesity variants
Common GWAS hits like FTO rs9939609 increase BMI by only ~0.4 kg/m² per allele, consistent with the general observation that rare coding variants carry larger per-allele effects.

A 2016 follow-up study⁵⁵ 2016 follow-up study
de Toro-Martín J et al., Obesity Science & Practice from Laval University extended the analysis to 3,693 participants from two Canadian cohorts, genotyping rs62623713 alongside two additional SYPL2 tagging SNPs (rs9661614 and rs485660). This study revealed a notable sex-specific dimension: tagging SNPs in the SYPL2 region associated with hip circumference specifically in women (FDR-corrected p = 1.7 × 10⁻²), suggesting that SYPL2 may preferentially influence a gynoid (hip-and-thigh) pattern of fat deposition in females. Male participants showed no significant associations with hip circumference, pointing to sex-hormone modulation of SYPL2's role in regional adipose distribution.

Critically, the evidence requires context: both studies used relatively modest sample sizes by modern GWAS standards, and the Jiao 2015 discovery cohort was a Swedish population, raising questions about generalizability. The variant has not yet been independently replicated in large-scale exome sequencing studies, and it does not appear in the NHGRI-EBI GWAS Catalog of genome-wide significant findings. The evidence level is therefore classified as emerging — a biologically plausible association with suggestive statistics, but requiring replication in larger, diverse cohorts before clinical utility can be established.

Practical Actions

For carriers of the G allele, the actionable message centers on lifestyle factors that are particularly relevant given the metabolic phenotype associated with SYPL2. Physical activity data specifically show SYPL2 expression is coupled to active status, suggesting that movement may partially compensate for the functional effects of the E99G variant. Women carrying G alleles who are concerned about gynoid fat distribution have additional context from the de Toro-Martín follow-up.

Given the emerging evidence status, specific dietary or supplementation protocols targeting SYPL2 biology are not yet established. The primary practical value of this variant lies in its contribution to personalized obesity risk assessment and motivating attention to body composition monitoring and physical activity behaviors that evidence links to SYPL2 expression.

Interactions

SYPL2's role in fat distribution shows sex-specific patterns, with the strongest associations in women for hip circumference. This suggests potential interaction with sex hormone signaling pathways in adipose tissue. The de Toro-Martín study found that tagging SNPs rs9661614 and rs485660 recapitulate much of the regional distribution phenotype, indicating these variants likely tag the same functional haplotype as rs62623713.

No documented compound interactions with other obesity-related variants (such as FTO rs9939609 or MC4R variants) have been studied for rs62623713, though pathway-level interactions in adipose biology are biologically plausible. Given the similar biological domain — adipose tissue and body composition — future studies may find additive effects with more common obesity variants.

The BCO1 gene encodes beta-carotene 15,15'-monooxygenase¹¹ beta-carotene 15,15'-monooxygenase
The enzyme that symmetrically cleaves one molecule of beta-carotene into two molecules of retinal, which is then reduced to retinol — the form of vitamin A used by the body, the key enzyme converting plant-based provitamin A into biologically active vitamin A. Most genetic studies of BCO1 focus on two coding variants — rs7501331 (Ala379Val) and rs12934922 (Arg267Ser) — that directly alter the enzyme's amino acid sequence. The rs6564851 variant operates at a different level entirely: located approximately 7.6 kb upstream of the BCO1 coding sequence, it is a regulatory SNP²² regulatory SNP
A non-coding variant that modifies gene expression or enzyme activity through changes to transcription factor binding sites, promoter elements, or chromatin accessibility rather than altering the protein sequence itself that emerged as the top genome-wide association signal for circulating beta-carotene levels across three independent cohorts.

The Mechanism

rs6564851 sits in an intergenic region at chromosome 16q23.2 (GRCh38 position 81,230,991), roughly 7.6 kb upstream from the BCO1 transcription start site — a location consistent with enhancer or promoter-proximal elements³³ enhancer or promoter-proximal elements
Regulatory DNA that can influence the transcription rate of a nearby gene; such elements often contain binding sites for transcription factors that activate or repress gene expression in a tissue-specific manner. The G allele is associated with reduced BCO1 enzyme activity. In a controlled pharmacokinetic study by Lietz et al. 2012⁴⁴ Lietz et al. 2012
Lietz G et al. Single nucleotide polymorphisms upstream from the β-carotene 15,15'-monoxygenase gene influence provitamin A conversion efficiency in female volunteers. J Nutr, 2012, the rs6564851 G allele was associated with a 48% reduction in BCMO1 catalytic activity in female volunteers. Carriers of the T allele (the better-converting allele) showed a positive correlation with the retinyl palmitate-to-beta-carotene ratio after a pharmacological beta-carotene dose (r = 0.41; P = 0.028), confirming that this upstream variant independently modulates the efficiency of the conversion step.

The net effect is a paradox that is characteristic of poor BCO1 converter status: because less beta-carotene is being cleaved, circulating beta-carotene levels rise while retinol production from plant sources falls. This is precisely what the GWAS data show — Ferrucci et al. 2009⁵⁵ Ferrucci et al. 2009
Ferrucci L et al. Common variation in the beta-carotene 15,15'-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study. Am J Hum Genet, 2009 found that each G allele is associated with a 0.27 standard deviation increase in plasma beta-carotene (p = 1.6 × 10⁻²⁴), while also reducing circulating lycopene, zeaxanthin, and lutein — a multi-carotenoid signature consistent with reduced cleavage activity across the entire carotenoid pathway.

BCO1 also possesses eccentric cleavage activity⁶⁶ eccentric cleavage activity
Asymmetric cleavage of carotenoids at positions other than 15,15', producing apo-carotenals and other bioactive metabolites including lycopene and lutein cleavage products; this secondary activity may explain why BCO1 variants affect non-beta-carotene carotenoids toward lycopene and other non-provitamin-A carotenoids, which explains the broader carotenoid profile changes seen with this variant beyond beta-carotene alone.

The Evidence

The founding association evidence comes from a multi-cohort GWAS by Ferrucci et al. 2009⁷⁷ Ferrucci et al. 2009
Ferrucci L et al. Common variation in the beta-carotene 15,15'-monooxygenase 1 gene affects circulating levels of carotenoids. Am J Hum Genet, 2009 in 3,941 participants across three studies (InCHIANTI, Women's Health and Aging Study, ATBC). The association with beta-carotene reached p = 1.6 × 10⁻²⁴ with effect sizes of 0.10–0.28 SDs per allele across multiple carotenoids. Importantly, plasma retinol itself showed no significant association — consistent with BCO1 impairment being compensated in people with mixed diets who obtain retinol directly from animal foods.

Mechanistic confirmation came from Lietz et al. 2012, who measured actual enzyme kinetics and pharmacokinetic responses in a controlled feeding study of female volunteers. The study was conducted exclusively in women — the functional activity reduction of 48% cannot be assumed to apply equally to males based on current data. Two nearby upstream variants (rs6420424, −59% activity; rs11645428, −51% activity) showed even larger effects, and all three variants together define a regulatory haplotype that substantially modulates BCO1 output independently of the coding variants.

The causal, not merely associative, nature of the rs6564851 effect on carotenoid metabolism was confirmed by a Mendelian randomization study by Perry et al. 2009⁸⁸ Perry et al. 2009
Perry JR et al. Circulating beta-carotene levels and type 2 diabetes — cause or effect? Diabetologia, 2009: the G allele raises circulating beta-carotene by 0.27 SD per allele as an instrumental variable, yet shows no association with type 2 diabetes (OR 0.98, 95% CI 0.93–1.04), confirming that the beta-carotene elevation reflects accumulation from reduced conversion, not higher dietary intake.

A small study by Feigl et al. 2014⁹⁹ Feigl et al. 2014
Feigl B et al. The relationship between BCMO1 gene variants and macular pigment optical density in persons with and without AMD. PLoS One, 2014 in 44 participants found that TT homozygotes had significantly higher macular pigment optical density than GG homozygotes (p < 0.01), consistent with the T allele facilitating better conversion and delivery of lutein and zeaxanthin to the macula. This effect was absent in AMD patients, possibly due to disease-related disruption of macular carotenoid transport.

Practical Implications

The central practical consequence is for people who rely on plant-based provitamin A. Dietary vitamin A comes in two forms: preformed retinol¹⁰¹⁰ preformed retinol
Found in animal products — liver, egg yolks, dairy, fatty fish — and absorbed directly without needing the BCO1 enzyme. The most reliable source for people with impaired beta-carotene conversion from animal sources and provitamin A carotenoids (primarily beta-carotene) from plants. G allele carriers convert less of their dietary beta-carotene to retinol; for omnivores, this is largely inconsequential because animal-source retinol bypasses BCO1 entirely. For vegans and vegetarians who rely exclusively on plant carotenoids for vitamin A, GG homozygosity represents a meaningful barrier to meeting vitamin A needs from diet alone.

The G allele is strikingly common in East Asian populations (~82% allele frequency), compared to ~51% in European and ~39% in African populations. This population difference is relevant in regions where plant-based diets are traditional — high G allele prevalence alongside plant-dominant diets may contribute to population-level vitamin A insufficiency patterns.

Macular health is a secondary concern: reduced BCO1 activity from the G allele may also lower the delivery of lutein and zeaxanthin to the retina, both of which are concentrated in the macula¹¹¹¹ macula
The central region of the retina responsible for sharp, detailed vision; its yellow pigmentation comes from concentrated lutein and zeaxanthin, which filter blue light and act as local antioxidants and protective against age-related macular degeneration.

Interactions

rs6564851 is on chromosome 16 (position 81,230,991), co-located with the BCO1 coding variants rs7501331 (Ala379Val) and rs12934922 (Arg267Ser). Although all three variants are in the BCO1 locus, the upstream regulatory variant and the coding variants represent distinct mechanisms — regulatory effects on expression versus structural effects on enzyme activity — and are expected to exert additive impairment when present together. Individuals carrying G alleles at rs6564851 alongside T alleles at rs7501331 and/or minor alleles at rs12934922 face cumulative BCO1 dysfunction combining both reduced enzyme quantity and reduced enzyme quality.

rs7834555, the other BCO1-related variant in the GeneOps database, is located on chromosome 8 (position 81,785,389) — a completely different chromosome from rs6564851. They are by definition not in linkage disequilibrium and represent fully independent genetic influences on carotenoid metabolism, likely through different biological mechanisms.

The broader regulatory haplotype at the rs6564851 locus includes rs6420424 and rs11645428, both of which show even larger activity reductions (59% and 51%, respectively) in the Lietz 2012 study. These three upstream variants likely tag the same or overlapping regulatory region and may be partially in LD with each other.

Sarcoidosis is a mysterious inflammatory disease in which the immune system forms granulomas¹¹ granulomas
Compact clusters of activated macrophages and lymphocytes that represent a failed attempt to wall off a perceived pathogen; in sarcoidosis no infectious agent is consistently found in the lungs and other organs. It strikes disproportionately in people of African descent and in Scandinavians, peaks between ages 25–45, and ranges from self-resolving (Löfgren's syndrome) to chronic and progressive lung disease. The gene ANXA11 — encoding annexin A11, a calcium-dependent membrane-binding protein — lies on chromosome 10q22.3, and rs7091565 sits in its 3' untranslated region, tagging a haplotype that alters sarcoidosis susceptibility by roughly 30–50%.

The Mechanism

Annexin A11 is a 56-kDa protein in the annexin superfamily, characterized by conserved C-terminal repeats that bind calcium and phospholipid membranes²² repeats that bind calcium and phospholipid membranes
These repeats are shared across all 12 human annexins; the unique N-terminal domain of ANXA11 is the region most divergent between family members and the functional hotspot for genetic variants. It is expressed broadly across tissues, with particularly high levels in the esophagus, heart, and lung. Its roles include regulating apoptosis (programmed cell death), cytokinesis, phagocytosis, and calcium-dependent signaling in immune cells — all processes central to the macrophage hyperactivation that characterizes sarcoidosis.

The functional missense variant rs1049550 (ANXA11 R230C) lies 13 kb downstream of rs7091565 within the same gene. This substitution — arginine to cysteine at position 230 of the protein — falls in the N-terminal regulatory domain and alters the protein's ability to interact with binding partners involved in apoptosis regulation. Importantly, rs7091565 and rs1049550 are in strong linkage disequilibrium³³ strong linkage disequilibrium
LD means the two alleles are inherited together on the same chromosome segment far more often than chance; carriers of one allele almost always carry the paired allele at the other site: the C allele at rs7091565 co-segregates with the C allele at rs1049550 (the arginine/risk haplotype), while the T allele at rs7091565 co-segregates with the T allele at rs1049550 (the cysteine/protective haplotype). This LD relationship makes rs7091565 a proxy marker for the functional R230C variant.

The mRNA expression of ANXA11 is not altered⁴⁴ mRNA expression of ANXA11 is not altered
This rules out differential transcription as the explanation; the R230C variant changes protein structure and apoptotic function, not expression level by rs1049550 genotype. Instead, the R230C substitution appears to modulate ANXA11's apoptotic activity directly: the arginine-230 (C allele) form is associated with impaired granuloma resolution, while the cysteine-230 (T allele) form may alter calcium-dependent interactions that improve macrophage death signaling and granuloma clearance.

The Evidence

rs7091565 was identified in the first genome-wide association study of sarcoidosis⁵⁵ first genome-wide association study of sarcoidosis
A GWAS scans ~440,000–1,000,000 common variants across the genome simultaneously, identifying statistical associations without assuming a biological hypothesis in advance by Hofmann et al. (Nature Genetics, 2008). In 499 German cases and 490 controls with validation in 1,649 cases and 1,832 controls, rs7091565 reached p = 1.0×10⁻⁵ in the validation cohort. The lead signal at the ANXA11 locus was rs2789679 (p = 3.0×10⁻¹³), with rs7091565 and the functional R230C variant (rs1049550) in its LD block.

The protective T allele has since been confirmed across multiple independent cohorts. A functional study⁶⁶ functional study
245 Czech sarcoidosis patients and 254 healthy controls; mechanistic cell biology experiments by Mrazek et al. (Genes & Immunity, 2011) found the T allele significantly less frequent in sarcoidosis cases (35%) versus controls (42%, OR 0.77, p=0.04). The T allele was particularly depleted in patients with pulmonary parenchymal infiltration compared to isolated hilar lymphadenopathy — suggesting it modifies not just susceptibility but disease severity.

The most comprehensive evidence comes from a meta-analysis⁷⁷ meta-analysis
Pooling data from 6 cohorts including European, African American, and Asian populations by Karakaya et al. (Cells, 2022): T allele protective in both Löfgren's syndrome (OR 0.69, 95% CI 0.52–0.92, p=0.01) and chronic sarcoidosis (OR 0.51, 95% CI 0.36–0.70, p=4×10⁻⁵), with a pooled OR of 0.70 (95% CI 0.66–0.75, p = 3.58×10⁻²⁹) — a highly significant and consistent protective signal. A separate multi-ethnic replication⁸⁸ multi-ethnic replication
1,689 cases and 1,252 controls in African Americans and European Americans by Levin et al. identified additional ANXA11 variants in African Americans and a significant interaction between rs1049550 and the HLA-DRA locus, pointing to a joint ANXA11–HLA axis in sarcoidosis immunopathology.

Practical Actions

The T allele at rs7091565 is substantially protective against sarcoidosis (approximately 30–50% reduced odds), while CC homozygotes carrying no protective T alleles have the highest risk at this locus. Sarcoidosis most commonly presents with dry cough, shortness of breath, fatigue, and bilateral hilar lymphadenopathy on chest X-ray. Skin involvement (erythema nodosum, lupus pernio), eye inflammation (uveitis), and cardiac arrhythmia are extrapulmonary manifestations.

For C-allele carriers, the most clinically actionable step is awareness: unexplained dry cough lasting more than 8 weeks, eye inflammation, or skin nodules warrant chest imaging, as sarcoidosis is often under-recognized in primary care. Pulmonary function testing and bronchoalveolar lavage can confirm diagnosis. Most cases are self-limited and require only monitoring; severe or progressive disease is treated with corticosteroids.

There is no dietary intervention proven to modify ANXA11-mediated sarcoidosis risk, but the inflammatory granuloma pathology can impair vitamin D metabolism — granuloma macrophages convert 25(OH)D to the active 1,25(OH)₂D form autonomously, leading to hypercalcemia in some patients. This makes calcium-containing supplements potentially contraindicated in active sarcoidosis, unlike most other inflammatory conditions.

Interactions

rs7091565 acts as a proxy for the functional rs1049550 R230C variant, so the two should not be treated as independent signals — they capture the same underlying biological effect. The sarcoidosis-risk haplotype at ANXA11 also includes rs2789679 (the lead GWAS SNP), rs2573346, and rs1953600, all in strong LD.

The interaction with HLA-DRA (rs9268839) is noteworthy: Levin et al. found a significant SNP-SNP interaction between rs1049550 and this HLA locus in African Americans, suggesting that ANXA11 risk is potentiated when combined with certain MHC class II alleles that drive the antigen-presentation arm of granuloma formation. This is biologically coherent — ANXA11 influences the apoptotic fate of macrophages forming the granuloma, while HLA-DRA governs the T-cell activation that recruits them. Risk at both loci simultaneously would amplify the inflammatory cascade from two independent points.

PTPN22 rs2476601 (R620W) is a broad autoimmune susceptibility variant that, while not studied specifically with ANXA11 in sarcoidosis, modulates T-cell receptor signaling and could compound ANXA11-mediated macrophage dysregulation in susceptible individuals.